Autolus Therapeutics plc (NASDAQ:AUTL) Short Interest Up 22.1% in December

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) was the recipient of a large increase in short interest in December. As of December 15th, there was short interest totalling 7,680,000 shares, an increase of 22.1% from the November 30th total of 6,290,000 shares. Based on an average daily trading volume, of 1,750,000 shares, the days-to-cover ratio is currently 4.4 days.

Autolus Therapeutics Stock Down 1.7 %

Shares of NASDAQ:AUTL traded down $0.04 during midday trading on Friday, hitting $2.26. The stock had a trading volume of 1,720,520 shares, compared to its average volume of 1,495,747. The company's 50-day moving average price is $3.18 and its 200-day moving average price is $3.71. Autolus Therapeutics has a fifty-two week low of $2.07 and a fifty-two week high of $7.45. The company has a market capitalization of $601.37 million, a P/E ratio of -1.87 and a beta of 1.98.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same quarter last year, the business posted ($0.26) EPS. Research analysts expect that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Redburn Atlantic raised shares of Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 price objective for the company in a report on Friday, November 15th. The Goldman Sachs Group raised Autolus Therapeutics from a "neutral" rating to a "buy" rating and increased their price target for the stock from $7.00 to $7.60 in a research report on Monday, November 18th. Finally, Needham & Company LLC restated a "buy" rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research note on Thursday, December 5th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $10.40.

Institutional Trading of Autolus Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. ProShare Advisors LLC bought a new stake in shares of Autolus Therapeutics during the 2nd quarter valued at approximately $43,000. Capstone Investment Advisors LLC acquired a new stake in Autolus Therapeutics in the third quarter valued at approximately $51,000. Daiwa Securities Group Inc. grew its stake in shares of Autolus Therapeutics by 2,659.7% during the second quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company's stock worth $55,000 after buying an additional 15,293 shares during the last quarter. Herbst Group LLC acquired a new position in shares of Autolus Therapeutics during the third quarter worth $91,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Autolus Therapeutics by 63.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company's stock valued at $139,000 after acquiring an additional 14,959 shares during the last quarter. 72.83% of the stock is currently owned by institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.